Wechselwirkungen · Spedra
Spedra 200 mg tablets · Abschnitt 4.5 · PDF-Seite 32
HOS-127509 · Präparat HOS-096405
Antihypertensives other than alpha-blockers A clinical study was conducted to assess the effect of avanafil on the potentiation of the blood pressure-lowering effects of selected antihypertensive medicinal products (amlodipine and enalapril). Results showed a mean maximum decrease in supine blood pressure of 2/3 mmHg compared to placebo with enalapril and 1/-1 mmHg with amlodipine when avanafil was co-administered. There was a statistically significant difference in maximum decrease from baseline in supine diastolic blood pressure with enalapril and avanafil only, which returned to baseline 4 hours after the dose of avanafil. In both cohorts, one subject experienced a decrease in blood pressure without symptoms of hypotension, which resolved within 1 hour of onset. Avanafil had no effect on the pharmacokinetics of amlodipine, but amlodipine increased the maximum and total exposure of avanafil by 28% and 60%, respectively (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): placebo (HOS-088378) enalapril (HOS-085479) amlodipine (HOS-086287)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-07T15:55:00Z · SHA-256 9f3a1264ef001d577393feb260b99952ed079148f452f8976f0be132f469d380 · Passage a0631ad8f146f5d084b14a50a2fbe7c3cbc8504d9177aa83f7123a401f3063ac · Zeichen 2668–3621 im Abschnitt